TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
It is a hard technique, which tends to break down large molecule ions during flight, since large molecules are particularly easy to fragment. Furthermore, large molecules are hard to volatilize without being degraded by heat.
== Biocontrol properties == Some P. fluorescens strains (CHA0 or Pf-5, for example) present biocontrol properties, protecting the roots of some plant species against parasitic fungi such as Fusarium or the oomycete Pythium, as well as some phytophagous nematodes, and insect pests. It is not clear exactly how the plant growth-promoting properties of P. fluorescens are achieved; theories include:
== Future research == The National Institute of Diabetes and Digestive Kidney Diseases sponsored a phase 2 clinical study in 2001 that would look at the effectiveness of leptin to treat severe insulin resistance. In the study, two children with severe insulin resistance of ages 11 and 13 with known a known defect in the insulin receptor. The goal for the study was to see if leptin could overcome insulin receptor defects by initiating molecules in the insulin-signal cascade. While no outcomes have yet been reported to date, the direction in which this clinical trial is heading is promising.
The major metabolite of progesterone in the urine is the 3α,5β,20α isomer of pregnanediol glucuronide, which has been found to constitute 15–30% of an injection of progesterone. Other metabolites of progesterone formed by the enzymes in this pathway include 3α-dihydroprogesterone, 3β-dihydroprogesterone, 20α-dihydroprogesterone, and 20β-dihydroprogesterone, as well as various combination products of the enzymes aside from those already mentioned. Progesterone can also first be hydroxylated (see below) and then reduced. Endogenous progesterone is metabolized approximately 50% into 5α-dihydroprogesterone in the corpus luteum, 35% into 3β-dihydroprogesterone in the liver, and 10% into 20α-dihydroprogesterone. Relatively small portions of progesterone are hydroxylated via 17α-hydroxylase (CYP17A1) and 21-hydroxylase (CYP21A2), into 17α-hydroxyprogesterone and 11-deoxycorticosterone (21-hydroxyprogesterone), respectively, and pregnanetriols are formed secondarily to 17α-hydroxylation. Even smaller amounts of progesterone may also be hydroxylated via 11β-hydroxylase (CYP11B1) and, to a lesser extent, via aldosterone synthase (CYP11B2) into 11β-hydroxyprogesterone. In addition, progesterone can be hydroxylated in the liver by other cytochrome P450 enzymes that are not steroid-specific. Catalyzed mainly by CYP3A4, 6β-Hydroxylation is the major transformation and is responsible for approximately 70% of cytochrome P450-mediated progesterone metabolism. Other routes include 6α-, 16α-, and 16β-hydroxylation.
Surface tension theory – according to this theory, emulsification takes place by reduction of interfacial tension between two phases Repulsion theory – According to this theory, the emulsifier creates a film over one phase that forms globules, which repel each other. This repulsive force causes them to remain suspended in the dispersion medium Viscosity modification – emulgents like acacia and tragacanth, which are hydrocolloids, as well as PEG (polyethylene glycol), glycerine, and other polymers like CMC (carboxymethyl cellulose), all increase the viscosity of the medium, which helps create and maintain the suspension of globules of dispersed phase
Sources: en.wikipedia.org
== Medicines == Treatments based on monoclonal antibodies have been produced related to CGRP or CGRP receptors. They have been shown to be effective in patients who experience migraine headaches, both with and without aura, and both episodic and chronic cluster headache. These are the first class of preventive medications originally designed and approved for people with migraine. Due to the nature of the monoclonal antibodies, they must be administered parenterally, preferably by injection. The first CGRP related medication approved by the FDA is called erenumab (trade name Aimovig), produced by pharmaceutical company Amgen and Novartis. It interacts with the CGRP receptor. It is injected once monthly with a dose of 70 or 140 mg. Few adverse effects were reported (most related to injection site reactions) and patients had a significant reduction in migraines. The second approved by the FDA is fremanezumab (trade name Ajovy), produced by the Teva Pharmaceuticals company. It interacts with the CGRP protein, whose expression is related to migraine attacks. It may be administered monthly or every three months, giving options for users. Trials have shown a reduction of greater than 50% of migraine days for those who responded. There were few significant side effects during trials, most related to injection site reactions. The third CGRP medication approved by the FDA is galcanezumab (trade name Emgality), produced by the Eli Lilly and Company. It interacts with the CGRP protein, whose expression is related to migraine attacks.
=== 2018–2021: Dancing on Ice and Diva === In January 2018, Collins appeared on Celebrity 100% Hotter in an attempt to change her style. Collins admitted she was "terrified" about having a makeover but said she was keen to try out some different trends. In February 2018, she took part in the fourth series of Celebs Go Dating. During her time on the show, Collins walked out on one of her dates within the first few minutes after he branded her a "diva" due to her being late, whilst she was also reprimanded by the dating experts after she failed to turn up to her date with Laurence, who was planning to take her to Paris. In June 2018, she released her second book, titled The GC: How to Be a Diva, in which she provides advice and self help for women to gain confidence. In an interview on Loose Women, she admitted to using a ghostwriter. She also guest starred in a promotional advert for Netflix's Orange Is the New Black. Collins went on to appear in Gemma Collins: Diva España, a one-off reality television special which aired in August 2018. In September 2018, Collins took part in the thirteenth series of Celebrity MasterChef. She was eliminated in the second round of the third heat after her sea bass served in greaseproof paper failed to impress the judges. In November 2018, Collins was the subject of a song released by Tallia Storm, titled "It's the GC (Diva Forever)". The song was featured in one of Collins' clothing advertisements for Boohoo.com and later became the theme song of her television franchise Gemma Collins: Diva.
=== How does dentinal bonding occur? === Dentin bonding refers to process of bonding a resin to conditioned dentin, where mineral component is replaced with resin monomers to form a biocomposite comprising dentin collagen and cured resin. The adhesive-dentin interface forms a tight and permanent bond between dentin and composite resins. It can be accomplished by either etch-and-rinse (total etch) or self-etch adhesives. In etch-and rinse, acid will dissolve the minerals to a certain depth and leaves the highly porous dentinal collagen network suspended in water. Then, the collagen network is infiltrated with resin monomers. After chemical polymerization of these monomers happen, activated by light cure, it will result in a polymer-collagen biocomposite, commonly known as the hybrid layer:
The neonatal fragment crystallizable (Fc) receptor (also FcRn, IgG receptor FcRn large subunit p51, or Brambell receptor) is a protein that in humans is encoded by the FCGRT gene. It is an IgG Fc receptor which is similar in structure to the MHC class I molecule and also associates with beta-2-microglobulin. In rodents, FcRn was originally identified as the receptor that transports maternal immunoglobulin G (IgG) from mother to neonatal offspring via mother's milk, leading to its name as the neonatal Fc receptor. In humans, FcRn is present in the placenta where it transports mother's IgG to the growing fetus. FcRn has also been shown to play a role in regulating IgG and serum albumin turnover. Neonatal Fc receptor expression is up-regulated by the proinflammatory cytokine, TNF, and down-regulated by IFN-γ.
Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine, or BLP25 liposome vaccine). The investigational therapeutic cancer vaccine is designed to induce a cellular immune response to cancer cells that express MUC1, a glycoprotein antigen that is widely over-expressed on common cancers such as lung cancer, breast cancer, prostate cancer, and colorectal cancer. The cellular immune response may lead to a rejection of tumor tissue expressing the MUC1 antigen.
Sources: en.wikipedia.org
Doak Barnett, who had travelled extensively in Xikang during the late 1940s, opined in 1993 that Liu's rule had been "one of the most oppressive and one of the worst warlord regimes in China." Academically, Western literature and scholarship treats Liu as a structural actor of Chinese frontier administration under pressure. To historian Joe Lawson, Liu's rule represents an evolution—not a break—of prior Qing-era ruler Zhao Erfeng's methods, influenced by pressures such as the political fragmentation of the Republican era. Another historian, James Leibold, frames Liu's domain as a "parasitic polity" within the larger Chinese state, a peripheral nuisance that disrupted the Nanjing government's attempts at centralization. Leibold also mentions Liu's adoption by the PRC's historiography, influenced by his defection to the communist side, that frames him in heroic terms as a frontier developer, a protector of minority groups, and an anti-imperialist. Here, the unsavory aspects of Liu's rule, especially the more colonial-esque measures, are attributed to Chiang Kai-shek. By September 2025, Liu Wenhui's former residence in Chengdu had become a museum. In January 2019, it was designated a party history education base by the Revolutionary Committee of the Chinese Kuomintang. Liu's residence has also been designated as a national priority protected site.
== Risks and complications == The overall risk of Mohs micrographic surgery complications is very low. Reported adverse event rates are between 0.7% and 2.6% according to large multi-center prospective studies. Infection of the surgical site, hematoma formation, bleeding, and suboptimal wound repair with dehiscence or ischemic necrosis are the most reported adverse events. Complication rates leading to permanent damage or requiring hospitalization are below 0.1% and no deaths have resulted from this procedure. Certain patient factors may make complications more likely. These include immunosuppression (after an organ transplant) and use of anticoagulants or anti-platelets (“blood thinners”). Increased risk is not independently associated with older age. There are surgical characteristics which also may increase the risk of complications including cancer location (extremities vs. forehead), large tumors with depth, and tumors requiring advanced flap or graft repairs.
== Awards == On 29 September 2014, President Goodluck Jonathan honoured Muhammad with the national award of the Officer of the Order of the Niger (OON) for his contributions to primary health care in Nigeria. In 2013, Muhammad won the Public Administrator of the Year Award (PAYA), organized annually by the Centre for Policy Development and Political Studies, Lagos, Nigeria. The centre said after announcing the winner that of the 10 nominees for the award, Muhammad scored 3,025 votes, representing over 50 percent of the total votes cast. He was praised for his efforts in "eradication of poliomyelitis; reduction in maternal and infant mortality; initiatives in addressing human resource challenges in the primary health care sub-sector; integration and decentralization of HIV/AIDs intervention in PHC services in over 1,500 PHC facilities." Muhammad also won the Kwame Nkrumah Leadership Award and the Africa Leadership Icon in 2014 at the 71st Conference of AASU, held at OATTU Conference Centre, in Accra, Ghana. The Kwame Nkrumah Leadership Award and Africa Leadership Icon 2014 are awarded by the All-Africa Students' Union (AASU).
Trump reinstated his "maximum pressure" campaign against Iran and sought a new set of negotiations to limit Iran's nuclear program. In March 2025, Trump sent a letter to Iranian supreme leader Ali Khamenei urging new negotiations and warning of military action if talks fail. On June 13, 2025, Israeli planes bombed sites in Iran associated with Iran's nuclear program. President Trump stated he was not involved, although Iranian leaders have said they do not believe this. There have been reports that Trump vetoed a plan to kill Iran's Ayatollah Khamenei, and that the United States communicated to Israel that Iran has not killed an American and discussions of killing political leaders should not be on the table. On June 21, 2025, the U.S. attacked three nuclear sites: the Fordow uranium enrichment facility, the Natanz nuclear facility, and Isfahan nuclear technology center. B-2 airplanes took off from the state of Missouri and made the 18-hour flight to Iran, being refueled multiple times en route. Entering Iranian airspace, fighter jets cleared space ahead of them, and a Navy sub fired more than 24 Tomahawk missiles. The leading B-2 dropped two Massive Ordnance Penetrators bombs (MOPs, or "bunker-busters") at the Fordo site. A total of 14 MOPs were dropped at two target sites.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.